Trials / Recruiting
RecruitingNCT06394804
A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
Combination Targeted and Hormonal treAtMEnt of Low-gradE Serous Ovarian Cancer in the upfroNt Setting
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The researchers are doing this study to find out whether the combination of avutometinib, defactinib, and letrozole is an effective treatment for people with low-grade serous ovarian cancer (LGSOC). The researchers will also look at the safety of this combination.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Avutometinib | Starting Dose 3.2 mg BIW for 3 of 4 weeks, Dose -1, 2.4 mg BIW for 3 of 4 weeks |
| DRUG | Defactinib | Starting Dose 200 mg BID for 3 of 4 weeks, Dose -1, 200 mg QD for 3 of 4 weeks |
| DRUG | Letrozole | 2.5 mg PO daily |
Timeline
- Start date
- 2024-04-29
- Primary completion
- 2027-04-01
- Completion
- 2027-04-01
- First posted
- 2024-05-01
- Last updated
- 2026-02-03
Locations
8 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06394804. Inclusion in this directory is not an endorsement.